Want to see CUPR full AI Analyst Report?
CUPR Stock Chart & Stats
$0.38
--
Market closed
$0.38
--
Day’s Range― - ―
52-Week Range$1.76 - $19.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.90M
Market Cap
$2.65M
Enterprise Value$15.53M
Total Cash (Recent Filing)$3.12M
Total Debt (Recent Filing)$482.72K
Price to Earnings (P/E)―
Beta1.15
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding920,625
10 Day Avg. Volume197,362
30 Day Avg. Volume2,899,437
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.08
Price to Sales (P/S)211.01
P/FCF Ratio-1.15
Enterprise Value/Market Cap5.87
Enterprise Value/Revenue579.61
Enterprise Value/Gross Profit-941.13
Enterprise Value/Ebitda-5.52
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA 510(k) ClearanceThe FDA 510(k) clearance for MEDIFLY (Lucilia cuprina) is a durable regulatory milestone that legitimizes Cuprina's dual‑species platform. It creates a competitive advantage in wound care, supports clinician adoption, and materially eases commercial and regulatory expansion in key regions over months to years.
Nasdaq Compliance RestoredRegaining compliance removes immediate listing risk and preserves continuous access to public equity markets and investor visibility. That sustained exchange listing supports longer‑term capital raising capacity, counterparty confidence, and liquidity needed to address persistent funding requirements.
Capital Reorg Increases Funding FlexibilityThe approved capital reorganization and larger authorised share capital provide structural flexibility to raise equity to fund operations or strategic initiatives. This improves the company's financing optionality over the medium term, reducing immediate liquidity constraints if management executes future issuances.
Bears Say
Persistent Negative Cash FlowOperating and free cash flow have been persistently negative and cash burn surged in 2025, indicating the business cannot self‑fund. This elevates execution and refinancing risk over the medium term, making future dilution, restrictive covenants or costly financing likely unless cash generation improves.
Deteriorating ProfitabilityGross profit turning negative and sharply wider losses in 2025 reflect weak product economics or adverse mix and rising costs. Small, volatile revenue with deteriorating margins limits operating leverage and suggests the company needs sustained commercial traction or structural cost cuts to restore durable profitability.
Historical Balance‑Sheet StrainProlonged negative equity through 2021–2024 implies prior solvency strain and reliance on external funding. Although equity turned positive in 2025, the historical weakness can persistently affect supplier, partner and investor confidence and may increase the cost or limit the availability of future financing.
Cuprina Holdings (Cayman) Limited Class A News
CUPR FAQ
What was Cuprina Holdings (Cayman) Limited Class A’s price range in the past 12 months?
Cuprina Holdings (Cayman) Limited Class A lowest stock price was $1.76 and its highest was $19.60 in the past 12 months.
What is Cuprina Holdings (Cayman) Limited Class A’s market cap?
Cuprina Holdings (Cayman) Limited Class A’s market cap is $2.65M.
When is Cuprina Holdings (Cayman) Limited Class A’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cuprina Holdings (Cayman) Limited Class A’s earnings last quarter?
Currently, no data Available
Is Cuprina Holdings (Cayman) Limited Class A overvalued?
According to Wall Street analysts Cuprina Holdings (Cayman) Limited Class A’s price is currently Overvalued.
Does Cuprina Holdings (Cayman) Limited Class A pay dividends?
Cuprina Holdings (Cayman) Limited Class A does not currently pay dividends.
What is Cuprina Holdings (Cayman) Limited Class A’s EPS estimate?
Cuprina Holdings (Cayman) Limited Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cuprina Holdings (Cayman) Limited Class A have?
Cuprina Holdings (Cayman) Limited Class A has 920,625 shares outstanding.
What happened to Cuprina Holdings (Cayman) Limited Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cuprina Holdings (Cayman) Limited Class A?
Currently, no hedge funds are holding shares in CUPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cuprina Holdings (Cayman) Limited Class A
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
Technical Analysis
GeoVax Labs
―
HCW Biologics
―
Calidi Biotherapeutics
―
Psyence Biomedical
―
Aspire Biopharma Holdings
―
Ownership Overview
―
Insiders
0.17% Mutual Funds
― Other Institutional Investors
99.83% Public Companies and
Individual Investors